Class summary at a glance.

Every drug in the Anticonvulsant / Neuropathic Pain Agent class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $1.26Bcombined across class
Total Rx claims: 67.0M17.3M unique beneficiaries
Generic mfrs (active): 56across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Gabapentin

Brand: GABARONE · 55.4M Part D claims (CY24) · 14.5M beneficiaries · First FDA approval: 1993-12-30

28 generic mfrs 136 plans require PA

Low NADAC$0.021

→

Avg plan cost$0.689

Part D spend $879.9M 33× spread, current vs floor

Class share

70%

of class CY24 spend

View profile →

Pregabalin

Brand: Lyrica · 11.6M Part D claims (CY24) · 2.8M beneficiaries · First FDA approval: 2004-12-30

28 generic mfrs 597 plans require PA

Low NADAC$0.046

→

Avg plan cost$1.07

Part D spend $382.3M 23× spread, current vs floor

Class share

30%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.